Literature DB >> 25912147

Management of severe pulmonary hypertension in patients undergoing mitral valve surgery.

Carlos D Davila1, Paul R Forfia.   

Abstract

OPINION STATEMENT: Pulmonary hypertension (PH) is simply defined as a mean pulmonary artery pressure greater than 25 mmHg at rest; however, may result from varying combinations of abnormal pulmonary artery (PA) blood flow, pulmonary vascular resistance (PVR), PA compliance, and pulmonary venous pressure. Mitral regurgitation (MR) allows for partial transmission of systemic arterial pressure into the pulmonary venous system. Mitral stenosis (MS) prevents pulmonary venous drainage into the left ventricle. In either case, the direct result is marked pressurization of the pulmonary venous system, with the primary cause of PH in significant mitral valve disease (PHMVD) being pulmonary venous hypertension (PVH). Chronic and severe PVH may then lead to muscularization of the pulmonary arterial bed, with a rise in PVR and loss of pulmonary arterial compliance that follows ("reactive" pulmonary vascular disease). Right heart dysfunction ensues once the PVR rises and the compliance falls to a point in which the right ventricle (RV) cannot overcome the increased afterload. However, it is worth emphasizing that in the setting of PHMVD, no matter the degree of mismatch between RV afterload and RV function, the root condition in the patient and cause of the PH remains severe MV disease. Without correction of the primary condition, the patient's heart failure (HF), PH, PVR, and RV dysfunction will remain or progress. Moreover, direct PH medical therapies are ineffective and may actually worsen left heart congestion in the setting of unremediated MVD. Therefore, although surgery may be a higher risk in some patients with PHMVD, the potential benefits justify the risks in the majority of cases. If needed, direct medical management of PH is far simpler and more effective once the MVD is corrected, given the degree of left heart congestion often improves dramatically. Therefore, corrective mitral valve intervention should be considered as the main and definitive treatment for these patients.

Entities:  

Year:  2015        PMID: 25912147     DOI: 10.1007/s11936-015-0382-1

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  41 in total

1.  Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure.

Authors:  M H Drazner; M A Hamilton; G Fonarow; J Creaser; C Flavell; L W Stevenson
Journal:  J Heart Lung Transplant       Date:  1999-11       Impact factor: 10.247

2.  National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008.

Authors:  Jersey Chen; Sharon-Lise T Normand; Yun Wang; Harlan M Krumholz
Journal:  JAMA       Date:  2011-10-19       Impact factor: 56.272

3.  Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy.

Authors:  S V Abramson; J F Burke; J J Kelly; J G Kitchen; M J Dougherty; D F Yih; F C McGeehin; J W Shuck; T P Phiambolis
Journal:  Ann Intern Med       Date:  1992-06-01       Impact factor: 25.391

4.  Mitral regurgitation: clinical patterns, pathophysiology and natural history.

Authors:  A Selzer; F Katayama
Journal:  Medicine (Baltimore)       Date:  1972-09       Impact factor: 1.889

5.  Impact of valve prosthesis-patient mismatch on pulmonary arterial pressure after mitral valve replacement.

Authors:  Mingzhou Li; Jean G Dumesnil; Patrick Mathieu; Philippe Pibarot
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

6.  Pulmonary capillary wedge pressure augments right ventricular pulsatile loading.

Authors:  Ryan J Tedford; Paul M Hassoun; Stephen C Mathai; Reda E Girgis; Stuart D Russell; David R Thiemann; Oscar H Cingolani; James O Mudd; Barry A Borlaug; Margaret M Redfield; David J Lederer; David A Kass
Journal:  Circulation       Date:  2011-11-30       Impact factor: 29.690

7.  Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.

Authors:  S M Palmer; L J Robinson; A Wang; J R Gossage; T Bashore; V F Tapson
Journal:  Chest       Date:  1998-01       Impact factor: 9.410

8.  High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors.

Authors:  Jackie D Corbin; Alfreda Beasley; Mitsi A Blount; Sharron H Francis
Journal:  Biochem Biophys Res Commun       Date:  2005-09-02       Impact factor: 3.575

9.  A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

Authors:  R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

10.  Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation.

Authors:  Miguel Angel Gómez-Sánchez; Carlos Saenz De La Calzada; Pilar Escribano Subías; Juan Francisco Delgado Jiménez; María Lázaro Salvador; Agustín Albarrán González; Luis Cea Calvo
Journal:  Eur J Heart Fail       Date:  2004-08       Impact factor: 15.534

View more
  3 in total

1.  Increased Mortality in Patients With Preoperative and Persistent Postoperative Pulmonary Hypertension Undergoing Mitral Valve Surgery for Mitral Regurgitation: A Cohort Study.

Authors:  Michael V Genuardi; Daniel Shpilsky; Adam Handen; Gabrielle VanSpeybroeck; Ann Canterbury; Michael Lu; Kayle Shapero; Ricardo A Nieves; Floyd Thoma; Suresh R Mulukutla; João L Cavalcante; Stephen Y Chan
Journal:  J Am Heart Assoc       Date:  2021-02-18       Impact factor: 5.501

Review 2.  Biomechanical Cues Direct Valvulogenesis.

Authors:  Neha Ahuja; Paige Ostwald; David Bark; Deborah Garrity
Journal:  J Cardiovasc Dev Dis       Date:  2020-05-19

3.  Myocardial Afterload Is a Key Biomechanical Regulator of Atrioventricular Myocyte Differentiation in Zebrafish.

Authors:  Neha Ahuja; Paige Ostwald; Alex Gendernalik; Elena Guzzolino; Letizia Pitto; David Bark; Deborah M Garrity
Journal:  J Cardiovasc Dev Dis       Date:  2022-01-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.